

REMARKS/ARGUMENTS

The Examiner has restricted the claims of the invention into the following Groups:

Group I, claims 1-9, drawn to a composition to treat Parkinson's disease;
Group II, claims 10-14, drawn to a method for the treatment of Parkinson's disease;
Group III, claims 15-23, drawn to a composition to treat retinal disease; and
Group IV, claims 24-28, drawn to a method for the treatment of retinal disease.


The Examiner is contending that the four groups of inventions do not relate to a single inventive concept and do not have unity of invention, because the special technical feature which links all of the claims, namely a composition comprising retinal pigmented cells in a biodegradable polymer gel, is not novel or is obvious in view of the art. Applicant respectfully disagrees with the Examiner's characterization of the art.

However, solely in order to advance prosecution in the instant application, Applicant elects Group I without traverse.

Conclusion

Applicant respectfully submits that the patent application is in condition for examination on the merits. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



Joseph G. Contrera, Reg. No. 44,628
LEYDIG, VOIT & MAYER

700 Thirteenth Street, N.W., Suite 300
Washington, DC 20005-3960
(202) 737-6770 (telephone)
(202) 737-6776 (facsimile)

Date: November 13, 2009

JGC/jj

J:\Cellular Bioengineering\266575US\266575 Response to RR.doc